Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Andrew John Partridge currently holds 155,865 shares of Turning Point Therapeutics, Inc. (TPTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Andrew John Partridge has been a net seller of TPTX stock. They have purchased $0 and sold $1.4M worth of shares.
Andrew John Partridge's most recent insider trade was on Oct 5, 2026, when they sold 7,873 shares at $146.39 per share.
Andrew John Partridge serves as Executive at Turning Point Therapeutics, Inc. (TPTX). They have executed 7 insider transactions totaling $1.4M over their tenure at the company.
Andrew John Partridge holds the position of Executive at Turning Point Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 6 years and currently hold a stake valued at $0.
Andrew John Partridge has shown a selling trading pattern, with $0 in total purchases and $1.4M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Andrew John Partridge was on Oct 5, 2026, when they sold $1.2M worth of GRAL shares. This transaction involved 7,873 shares at $146.39 per share.
Andrew John Partridge currently owns 155,865 shares of Turning Point Therapeutics, Inc. (TPTX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Andrew John Partridge's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Andrew John Partridge has 7 Form 4 filings on record as an insider at Turning Point Therapeutics, Inc..
Set alerts for Andrew John Partridge and 40,000+ other insiders.